Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
AstraZeneca
Matthew J Ellis; Antonio Llombart-Cussac; David Feltl; John A Dewar; Marek Jasiówka; Nicola Hewson; Yuri Rukazenkov; John F R Robertson